沙库巴曲缬沙坦和缬沙坦在慢性心力衰竭患者中的应用效果对比

Comparison of the Efficacy of Sacubactril Valsartan and Valsartan in Patients with Chronic Heart Failure

目的分析沙库巴曲缬沙坦和缬沙坦在慢性心力衰竭患者治疗中的应用效果。方法选取2022年5月—2023年5月于山东中医药大学附属医院东营医院确诊的132例慢性心力衰竭患者为研究对象,以随机数表法分为参照组(n=66)和观察组(n=66),在常规治疗基础上,参照组以缬沙坦治疗,观察组以沙库巴曲缬沙坦治疗,观察其心功能、血管内皮功能及心力衰竭标志物水平变化和安全性。结果治疗后,观察组左心室收缩末期内径(left ventricular end-systolic diameter,LVESD)、左心室舒张末期内径(left ventricular end-diastolic diameter,LVEDD)水平均明显低于参照组,左心室射血分数(left ventricular ejection fraction,LVEF)明显高于参照组,差异有统计学意义(P<0.05)。治疗后,观察组一氧化氮(nitric oxide,NO)、一氧化氮合酶(nitric oxide synthase,NOS)水平均明显高于参照组,内皮素(endothelin,ET)明显低于参照组,差异有统计学意义(P<0.05)。治疗后,观察组B型钠尿肽(B-type natriuretic peptide,BNP)、N末端脑钠肽前体(N-terminal pro-B-type natriuretic peptide,NT-proBNP)水平均明显低于参照组,差异有统计学意义(P<0.05)。参照组不良反应总发生率为6.06%,观察组为4.55%,差异无统计学意义(χ^(2)=0.151,P=0.698)。结论在慢性心力衰竭患者的用药治疗中,沙库巴曲缬沙坦治疗为患者带来的获益要明显大于缬沙坦,在帮助患者增强心功能方面,沙库巴曲缬沙坦更具优势,更有利于改善患者血管内皮功能,降低心力衰竭标志物表达水平,且不良反应少。

Objective To analyze the effect of sacubactril valsartan and valsartan in the treatment of chronic heart failure.Methods 132 patients with chronic heart failure diagnosed from May 2022 to May 2023 at Dongying Hospital,Affiliated Hospital of Shandong University of Traditional Chinese Medicine were selected as the research subjects.They were randomly divided into a reference group(n=66)and an observation group(n=66)using a random table number method.On the basis of routine treatment,the reference group was treated with valsartan,while the observation group was treated with sarcubatrix valsartan.The changes in cardiac function,vascular endothelial function,and heart failure biomarker levels and safety were observed.Results After treatment,the level of left ventricular end-systolic diameter(LVESD)and left ventricular end-diastolic diameter(LVEDD)in the observation group were significantly lower than those in the reference group,while left ventricular ejection fraction(LVEF)was significantly higher than that in the reference group,the difference was statistically significant(P<0.05).After treatment,the levels of nitric oxide(NO)and nitric oxide synthase(NOS)in the observation group were significantly higher than those in the reference group,while endothelin(ET)was significantly lower than that in the reference group,the difference was statistically significant(P<0.05).After treatment,the levels of B-type natriuretic peptide(BNP)and N-terminal pro-B-type natriuretic peptide(NT-proBNP)in the observation group were significantly lower than those in the reference group,the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the reference group was 6.06%,while in the observation group it was 4.55%,the difference was not statistically significant(χ^(2)=0.151,P=0.698).Conclusion In the treatment of patients with chronic heart failure,the benefit of sacubactril valsartan treatment is significantly greater than that of valsartan.In terms of helping patients to enhance cardiac function,sacubactril valsartan has more advantages,which is more conducive to improving the vascular endothelial function of patients,reducing the expression level of heart failure markers,and fewer adverse reactions.